Jenburkt Pharmaceuticals Intrinsic Value
JENBURPH Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1645.60 | ₹1316.48 - ₹1974.72 | +50.2% | EPS: ₹74.80, Sector P/E: 22x |
| Book Value Method | asset | ₹860.00 | ₹774.00 - ₹946.00 | -21.5% | Book Value/Share: ₹430.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹835.00 | ₹751.50 - ₹918.50 | -23.8% | Revenue/Share: ₹417.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1197.38 | ₹1077.64 - ₹1317.12 | +9.3% | EBITDA: ₹49.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹752.02 | ₹601.62 - ₹902.42 | -31.4% | CF Growth: 8.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹681.81 | ₹613.63 - ₹749.99 | -37.8% | EPS Growth: 11.4%, Fair P/E: 9.1x |
| Growth Adjusted P/E | growth | ₹1159.40 | ₹1043.46 - ₹1275.34 | +5.8% | Revenue Growth: 6.7%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1155.00 | ₹1039.50 - ₹1270.50 | +5.4% | ROE: 19.2%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹850.70 | ₹765.63 - ₹935.77 | -22.4% | EPS: ₹74.80, BVPS: ₹430.00 |
Want to compare with current market value? Check JENBURPH share price latest .
Valuation Comparison Chart
JENBURPH Intrinsic Value Analysis
What is the intrinsic value of JENBURPH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jenburkt Pharmaceuticals (JENBURPH) is ₹860.00 (median value). With the current market price of ₹1095.65, this represents a -21.5% variance from our estimated fair value.
The valuation range spans from ₹681.81 to ₹1645.60, indicating ₹681.81 - ₹1645.60.
Is JENBURPH undervalued or overvalued?
Based on our multi-method analysis, Jenburkt Pharmaceuticals (JENBURPH) appears to be trading above calculated value by approximately 21.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.14 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 19.2% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Jenburkt Pharmaceuticals
Additional stock information and data for JENBURPH
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹28 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹17 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹20 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |